MTOR and pancreatic neuroendocrine tumor: In pancreatic NETs (pNETs), mutations of the epigenetic regulators MEN1 and DAXX/ATRX have been described in 44% and 43% of tumors respectively, while alterations of the mammalian target of rapamycin (mTOR) pathway have been found in 14% of the specimens [3].